Bellevue Group AG Buys Shares of 7,700 NewAmsterdam Pharma (NASDAQ:NAMS)

Bellevue Group AG purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 7,700 shares of the company’s stock, valued at approximately $128,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Decheng Capital LLC acquired a new position in NewAmsterdam Pharma during the 2nd quarter worth $7,684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after purchasing an additional 221,305 shares in the last quarter. Millennium Management LLC increased its holdings in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after buying an additional 217,902 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in NewAmsterdam Pharma by 30.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after buying an additional 202,250 shares in the last quarter. Finally, Affinity Asset Advisors LLC lifted its holdings in NewAmsterdam Pharma by 47.9% during the 2nd quarter. Affinity Asset Advisors LLC now owns 423,155 shares of the company’s stock worth $8,129,000 after buying an additional 136,955 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Down 4.6 %

Shares of NASDAQ NAMS opened at $19.85 on Monday. NewAmsterdam Pharma has a 1-year low of $8.90 and a 1-year high of $26.35. The business’s fifty day moving average price is $19.55 and its two-hundred day moving average price is $18.57.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $33.80.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,803 shares of company stock worth $1,755,307. Insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.